Fast Forward, LLC and Provid Pharmaceuticals announce partnership for development of PV-267, a unique compound intended to redirect the abnormal immune response in MS
Fast Forward, LLC, the National Multiple Sclerosis Society’s subsidiary devoted to bridging the gap between research and drug development, have announced a partnership to support Provid’s preclinical studies of PV-267.
To read more about this as reported by the US National MS Society click here.
